With a focus on patient access – and an army of high-powered sales professionals – Agile remains fully committed to women’s health, freedom, and flexibility
In the corporate medical sector’s frenzy to address practically every aspect of men’s health, oftentimes women’s needs get put on the back burner.
Mindfully but aggressively tackling this pressing issue is New Jersey-headquartered Agile Therapeutics, a forward-thinking commercial-stage company dedicated to building a robust women’s health franchise while bringing products to market that keep pace with the changing needs of today’s women.
Agile Therapeutics seeks to broaden its women’s health portfolio, including in areas of unmet medical need. Already, however, the company is redefining the women’s contraceptive market with a product that’s been approved by the FDA.
And even beyond the innovative approach to women’s health products, Agile’s backed by a sales force that’s strongly targeted while also providing volume and reach – more customers reached, mission accomplished.
A Closer Look at AGRX Stock
If you’re on the lookout for a dip-buying opportunity, it doesn’t get any better than AGRX stock. The share price simply doesn’t match the intrinsic value of the company – but I suspect that this mispricing will be corrected soon enough.
While Agile Therapeutics continues to advance state-of-the-art health-care solutions, AGRX stock is largely still unrecognized by the trading community.
On the first trading day of May, the stock was trading for $1.78, but it’s been significantly higher than that. In fact, AGRX’s 52-week range is $1.70 to $3.89, so you’ve got a rare opportunity to buy a potential runner at the bottom of its range.
The remainder of 2021 could provide some breakthrough moments for Agile Therapeutics – and along with them, some powerful, sustained breakouts for AGRX stock.
A Proven Solution, Just for Her
Agile Therapeutics’ flagship product is known as Twirla. It’s based on the simple concept that for many women, a weekly, non-invasive birth control method just makes sense.
Here’s the scoop: Twirla is a weekly hormonal birth control patch for women with a body mass index (BMI) less than 30 kg/m2 who can become pregnant. It involves no painful procedures, there’s nothing to insert, and there’s no same-time-every-day pill routine to deal with.
Technically, Twirla is classified as levonorgestrel and ethinyl estradiol, and uses a transdermal system. Launched in December 2020, Twirla is Agile’s first FDA-approved product, and it’s truly unique even beyond the fact that it’s a non-daily, non-invasive contraceptive patch.
That’s because it provides the lowest dose of estrogen available in a transdermal option, along with a 120 mcg daily dose of levonorgestrel, a well-known progestin with a long history of use in the category.
And while Agile Therapeutics does plan to broaden the company’s women’s health product portfolio, Twirla by itself applies to a massive, $4.1 billion addressable market.
Plus, Twirla’s safety profile was recently affirmed in a Phase 3 SECURE clinical trial. SECURE study Lead Author and Primary Investigator Anita Nelson concluded that the data supports “the safety and tolerability of Twirla in women within BMI 25-30 kg/m2 as well as those with BMI < 25 kg/m2.”
Selling the Science
But of course, this wouldn’t mean much if Agile didn’t have ways to raise brand awareness – and believe me, the company’s got this covered.
In a groundbreaking sales strategy, Agile Therapeutics has teamed up with a contract sales organization called Syneos to support a flexible, insight-driven approach to marketing Twirla.
With Syneos, Agile has effectively recruited an army of 73 sales professionals (including 8 all-virtual sales professionals), all aligned to the highest-volume U.S. geographies and target health-care provider offices.
By aligning with the Syneos sales team Agile has been able to bypass the inefficient, traditional call plan approaches and targeting, which can lead to inefficient territory design.
Instead, the partnership with Syneos has yielded a much more modern and strategic approach in marketing Twirla:
- Enhanced training on effective virtual interactions
- 8-week virtual training program features best-in-class clinical knowledge, virtual selling skills, competitive/reimbursement landscape understanding
- All materials approved for virtual/face-to-face interactions
- Upgraded technology for virtual interactions
- Field teams hired/trained/engaged in mid-October, several months prior to Twirla product launch
- Regional sales leaders empowered to allocate resources to ensure most effective coverage within geographies
- Territories/targets profiled to understand office protocols/Covid-19 policies
The result: a national sales dream team to promote brand awareness and bring a leading-edge contraceptive solution to eligible women throughout the nation.
The Bottom Line
Agile Therapeutics deserves to be recognized for the company’s advancements in the science of women’s reproductive health and freedom.
And with a sales force that’s unmatched and unstoppable, the brand recognition will come – and so will the future returns for patient investors in AGRX stock.
